At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Daratumumabdrug
Likely dose
Daratumumab 16 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Phase 2 Study to Assess the Clinical Efficacy and Safety of Daratumumab in Patients With Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type
In Brief
A Phase 2 clinical trial evaluating Daratumumab for Lymphoma. Completed, enrolled 32 participants across 17 sites in 5 countries.
Detailed Summary
The purpose of this study is to assess the clinical efficacy and safety of daratumumab in relapsed or refractory natural killer/T-cell lymphomas (NKTCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesChina, Hong Kong, Singapore, South Korea, Taiwan
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartFeb 2017
Primary CompletionJan 2020
Study CompletionJan 2020
TodayJul 2026
First PostedOct 7, 2016
Enrollment StartFeb 14, 2017
Primary CompletionJan 2, 2020
Study CompletionJan 7, 2020
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 9.7 years ago
Interventions
Daratumumabdrug
Participants will receive daratumumab 16 mg/kg as intravenous infusion.